An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma

Blood

Volumn 112, Issue 10, 2008, Pages 4235-4246

  Xiong, Wei ^a   Wu, Xiaosong ^a   Starnes, Sarah ^a   Johnson, Sarah K ^a,b   Haessler, Jeff ^c   Wang, Siqing ^a   Chen, Lijuan ^a   Barlogie, Bart ^a   Shaughnessy Jr , John D ^a   Zhan, Fenghuang ^a,d  

^a Myeloma Institute for Research and Therapy   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LOSS; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; UPREGULATION; DNA DAMAGE; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; RISK FACTOR; TUMOR CELL LINE; TUMOR GENE;

AGED; CELL LINE, TUMOR; DNA DAMAGE; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 58149165366     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-10-119123     Document Type: Article

References (48)

1. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276-2284.
2. Carrasco DR, Tonon G, Huang Y, et al. High-resolution genomic profiles define distinct clinicopathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006;9:313-325.
3. Paydas S, Sahin B, Seyrek E, Zorludemir S. P53 mutations in multiple myeloma. Mol Pathol. 1997; 50:329.
4. Owen RG, Davis SA, Randerson J, et al. P53 gene mutations in multiple myeloma. Mol Pathol. 1997;50:18-20.
5. Ollikainen H, Syrjanen S, Koskela K, Pelliniemi TT, Pulkki K. P53 gene mutations are rare in patients but common in patient-originating cell lines in multiple myeloma. Scand J Clin Lab Invest. 1997;57:281-289.
6. Yasuga Y, Hirosawa S, Yamamoto K, Tomiyama J, Nagata K, Aokia N. N-ras and p53 gene mutations are very rare events in multiple myeloma. Int J Hematol. 1995;62:91-97.
7. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. P53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood. 1993;81:128-135.
8. Chang H, Qi C, Yi QL, Reece D, Stewart AK. P53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood. 2005;105: 358-360.
9. Ortega MM, Melo MB, De Souza CA, Lorand- Metze I, Costa FF, Lima CS. A possible role of the p53 gene deletion as a prognostic factor in multiple myeloma. Ann Hematol. 2003;82:405-409.
10. Drach J, Ackerman J, Kaufmann H, Konigsberg R, Huber H. Deletions of the p53 gene in multiple myeloma. Br J Haematol. 2000;108:886.
11. Carlebach M, Amiel A, Gaber E, et al. Multiple myeloma: monoallelic deletions of the tumor suppressor genes TP53 and RB1 in long-term followup. Cancer Genet Cytogenet. 2000;117:57-60.
12. Avet-Loiseau H, Li JY, Godon C, et al. P53 deletion is not a frequent event in multiple myeloma. Br J Haematol. 1999;106:717-719.
13. Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional- dose chemotherapy. Blood. 1998;92:802- 809.
14. Kho PS, Wang Z, Zhuang L, et al. P53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem. 2004; 279:21183-21192.
15. Cawley S, Bekiranov S, Ng HH, et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell. 2004; 116:499-509.
16. Kannan K, Kaminski N, Rechavi G, Jakob-Hirsch J, Amariglio N, Givol D. DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1. Oncogene. 2001;20:3449- 3455.
17. Kannan K, Amariglio N, Rechavi G, et al. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene. 2001;20:2225-2234.
18. Zhao R, Gish K, Murphy M, et al. Analysis of p53- regulated gene expression patterns using oligonucleotide arrays. Genes Dev. 2000;14:981-993.
19. Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B. Identification and classification of p53-regulated genes. Proc Natl Acad Sci U S A. 1999;96:14517-14522.
20. Wei CL, Wu Q, Vega VB, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell. 2006;124:207-219.
21. Zhan F, Colla S, Wu X, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007;109:4995-5001.
22. Zhan F, Barlogie B, Arzoumanian V, et al. Geneexpression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109:1692-1700.
23. Shaughnessy JD Jr, Haessler J, van Rhee F, et al. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol. 2007;137:530-536.
24. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138:176-185.
25. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006; 108:2020-2028.
26. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021- 1030.
27. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stemcell transplantation. Blood. 2006;108:1724-1732.
28. Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood. 2003;101:3849-3856.
29. Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J Jr. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood. 2003;101:1128-1140.
30. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745-1757.
31. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483-2494.
32. Trono D. HIV-based vectors: getting the best out of the worst. J Gene Med. 2000;2:61-63.
33. Colla S, Zhan F, Xiong W, et al. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood. 2007;109:4470- 4477.
34. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol. 1997;15:871-875.
35. IARC. TP53 mutation database. http://wwwp53.iarc.fr.
36. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98:5116-5121.
37. Zhan F, Barlogie B, Mulligan G, Shaughnessy JD Jr, Bryant B. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with highdose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood. 2008;111:968- 699.
38. Chng WJ, Kuehl WM, Bergsagel PL, Fonseca R. Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. Leukemia. 2008;22:459-461.
39. Sun Y. P53 and its downstream proteins as molecular targets of cancer. Mol Carcinog. 2006;45: 409-415.
40. Wu GS, Burns TF, McDonald ER 3d, et al. KILLER/DR5 is a DNA damage-inducible p53- regulated death receptor gene. Nat Genet. 1997; 17:141-143.
41. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia. 1999;13:1817-1824.
42. Gomez-Benito M, Martinez-Lorenzo MJ, Anel A, Marzo I, Naval J. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp Cell Res. 2007;313:2378- 2388.
43. Qi R, An H, Yu Y, et al. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res. 2003;63:8323-8329.
44. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2004;103:3503-3510.
45. Hellborg F, Qian W, Mendez-Vidal C, et al. Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein. Oncogene. 2001;20:5466-5474.
46. Mendez Vidal C, Prahl M, Wiman KG. The p53- induced Wig-1 protein binds double-stranded RNAs with structural characteristics of siRNAs and miRNAs. FEBS Lett. 2006;580:4401-4408.
47. Obad S, Olofsson T, Mechti N, Gullberg U, Drott K. Expression of the IFN-inducible p53-target gene TRIM22 is down-regulated during erythroid differentiation of human bone marrow. Leuk Res. 2007;31:995-1001.
48. van Everdink WJ, Baranova A, Lummen C, et al. RFP2, c13ORF1, and FAM10A4 are the most likely tumor suppressor gene candidates for Bcell chronic lymphocytic leukemia. Cancer Genet Cytogenet. 2003;146:48-57.